Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02714595 · ClinicalTrials.gov registry record · Phase 3
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
A Phase 3 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
NCT02714595 is a Phase 3 study that has completed, run by Shionogi. The registered enrollment target is 152 participants.
The verdict
NCT02714595, a Phase 3 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
Study Summary
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
Interventions
- DRUG Cefiderocol
- DRUG Best Available Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2016-09-07 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02714595
The ClinicalTrials.gov registry entry for NCT02714595 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cefiderocol is the first listed.
NCT02714595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02714595 about?
NCT02714595 is a clinical study titled "Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens". This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
What is the current status of trial NCT02714595?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2016-09-07. Estimated completion is 2019-04-22.
What interventions are being tested in trial NCT02714595?
The interventions under investigation include: Cefiderocol (DRUG), Best Available Therapy (DRUG).
Who is sponsoring clinical trial NCT02714595?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.